VANDELLI, Carmen
 Distribuzione geografica
Continente #
NA - Nord America 2.112
EU - Europa 843
AS - Asia 251
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
SA - Sud America 1
Totale 3.210
Nazione #
US - Stati Uniti d'America 2.108
GB - Regno Unito 298
SE - Svezia 206
CN - Cina 93
IT - Italia 91
DE - Germania 83
TR - Turchia 75
HK - Hong Kong 70
UA - Ucraina 57
FI - Finlandia 40
BG - Bulgaria 26
BE - Belgio 12
NL - Olanda 11
FR - Francia 9
IE - Irlanda 6
IN - India 4
CA - Canada 3
EU - Europa 2
IR - Iran 2
MY - Malesia 2
PL - Polonia 2
SG - Singapore 2
AU - Australia 1
BZ - Belize 1
CL - Cile 1
ID - Indonesia 1
IL - Israele 1
PT - Portogallo 1
RO - Romania 1
VN - Vietnam 1
Totale 3.210
Città #
Fairfield 284
Southend 229
Woodbridge 222
Chandler 198
Ashburn 197
Houston 175
Ann Arbor 127
Wilmington 122
Jacksonville 119
Nyköping 97
Dearborn 89
Seattle 84
Cambridge 78
Hong Kong 70
Izmir 50
Beijing 30
Princeton 30
San Diego 30
Sofia 26
Des Moines 25
Eugene 25
Boardman 19
Modena 17
Shanghai 17
Helsinki 12
Amsterdam 11
Brussels 11
London 10
New York 9
Reggio Nell'emilia 9
Falls Church 8
Los Angeles 8
Dublin 6
Redwood City 6
San Mateo 6
Bologna 5
Bremen 5
Hefei 5
Auburn Hills 4
Kunming 4
Milan 4
Norwalk 4
Turku 4
Grafing 3
Guangzhou 3
Kilburn 3
Augusta 2
Busto Arsizio 2
Leawood 2
Nanchang 2
Parma 2
Philadelphia 2
Prescot 2
Toronto 2
Tulare 2
Verona 2
Wuhan 2
Adelaide 1
Ankara 1
Argelato 1
Belize City 1
Belpasso 1
Calcinaia 1
Cantalice 1
Casapulla 1
Cassano Magnago 1
Changchun 1
Chiswick 1
Cilacap 1
Citta 1
Dongguan 1
Dung 1
Faenza 1
Falkenstein 1
Fuzhou 1
Gandhi Nagar 1
Hounslow 1
Lanzhou 1
Leiria 1
Mariano Comense 1
Mezzocorona 1
Monmouth Junction 1
Nanjing 1
Ottawa 1
Polesella 1
Pune 1
Rimini 1
Rockville 1
Rome 1
Saponara 1
Schoten 1
Shenyang 1
Solbiate Arno 1
Southwark 1
Targu 1
Tel Aviv 1
Torino 1
Trecate 1
Wandsworth 1
Warsaw 1
Totale 2.565
Nome #
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases 200
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 199
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 161
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 153
Fibrosis progression in HCV carriers with mild hepatitis who possess the high-repetition variant of the DRD4 gene, a genetic marker for binge-drinking and risk-seeking behavior: a longitudinal study 152
Chronic hepatitis C and psychosocial distress 151
Parametri predittivi e risposta sostenuta alla terapia antivirale combinata nell'epatite cronica attivva HCV correlata (ECA HCV) 149
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy 140
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve mono-infected HCV patients. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milano,Italia, 23-27 Aprile, 2008. 138
Lack of evidence of sexual transmission of hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study 136
The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases 136
The virologic and histologic status in anti HCV+ve subjects with normal ALT levels: results of a ten year prospective follow-up study. 118
Analysis of factors involved in fibrosis progression among hepatitis C virus carriers with normal alanine aminotransferares. 41st Annual Meeting of the European Association for the Study of the Liver (EASL).Vienna, Austria, 26-30 Aprile 2006. 117
A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon 115
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve mono-infected HCV patients. 112
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 110
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naive hepatitis C patients. 105
Genetic polymorphisms of interleukin-6 modulates fibrosis progression in mild chronic hepatitis C. 103
Long-term interferon therapy in patients with refractory chronic hepatitis C: effect on histological liver damage and hepatocellular carcinogenesis. 99
Demographic, etiological and clinical features of 500 consecutive patients with liver cirrhosis at the onset of the first episode of decompensation. 50th Anniversary Meeting of the International Association for the Study of Liver Diseases (AASLD). San Francisco, 31 Ottobre- 4 Novembre 2008. 99
Demographic, etiological and clinical features of 500 consecutive patients with liver cirrhosis at the onset of the first episode of decompensation. 50th Anniversary Meeting of the International Association for the Study of Liver Diseases (AASLD) 96
Prediciting the natural history of patients with epatitis C and persistently normal transaminases: a longitudinal long term study with dual biopsies. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). 95
Metodologia per l’adozione di linee guida cliniche in Medicina Interna. 94
Health-related quality of life in recent and long standing chronic HCV infection. 92
Hepatitis C virus carriers with normal alanine aminotransferases: analysis of factors involved in fibrosis progression. 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). Barcellona, Spagna, 11-15 aprile 2007. 91
Prediciting the natural history of patients with epatitis C and persistently normal transaminases: a longitudinal long term study with dual biopsies. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milano, Italia, 23-27 Aprile, 2008. 74
Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C 2
Totale 3.237
Categoria #
all - tutte 11.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.243


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019247 0 0 0 0 0 0 0 0 0 30 96 121
2019/2020572 32 43 13 43 48 105 99 53 50 21 39 26
2020/2021565 47 11 44 69 38 43 90 67 21 57 43 35
2021/2022476 9 58 50 59 13 24 26 13 56 34 90 44
2022/2023526 61 68 36 46 63 92 3 52 84 2 11 8
2023/2024281 8 21 14 32 49 19 52 79 6 1 0 0
Totale 3.237